Shares of nano-cap company Minerva Neurosciences, Inc. (NERV) plunged over 60% on Tuesday morning after the company said it received a Complete Response Letter from the U.S. Food and Drug Administration for New Drug Application for Roluperidone for the treatment of negative symptoms in patients with schizophrenia.
NERV is currently trading at $2.6700, down $4.1300 or 60.74%, on the Nasdaq. The stock opened its trading at $3.3000 after closing Monday's trading at $6.8000. The stock has traded between $1.5000 to $13.4900 in the past 52-week period.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.